Early Diagnosis of Breast Cancer
Challenged by a large uncertainty on Positive Predictive Value in ACR 4 category (2% – 95%)
Leads to overconsumption of Macrobiopsies which are :
- Deleterious for the patient
- Time-consuming for the doctor
- Costly for the Health System
Cancer detected at an ADVANCED STAGE
Cancer detected at an EARLY STAGE
millions mammograms WW per year
millions mammograms contain microcalcifications
millions microcalcifications are suspect ACR>4
millions microcalcifications are benign
A game-changing technology
XIMED is a deeptech startup revolutionizing breast cancer diagnostics through advanced X-ray phase-contrast imaging.
Born from cutting-edge research and a patented technology developed at ALPhANOV, XIMED offers a new generation of imaging systems capable of revealing subtle tissue contrasts invisible to conventional mammography.
Our Technology, provides ultra-precise characterization of microcalcifications—key early indicators of breast cancer—while significantly reducing unnecessary biopsies and minimizing radiation exposure.
Based in the heart of the photonics hub at the Institut d’Optique d’Aquitaine, XIMED leverages the region’s dynamic ecosystem and benefits from strong institutional support, including CRNA and Bpifrance.
Our mission is to empower radiologists with more accurate, earlier, and safer diagnostic tools—because behind every image is a life that matters.
About Us
Our research center, located in Talence, Gironde, is dedicated to advancing medical imaging technologies.
With a growing team of experts and expanding partnerships with leading institutions, we drive innovation to enhance diagnostic precision.
Our commitment to research fosters groundbreaking solutions for early disease detection and improved patient care.
